A US Biosimilar Turning Point Approaches, With Work To Do

2022 will be an important year for biosimilar manufacturers as the market expands into new areas like ophthalmology and insulin, and as the Humira US biosimilar entry nears in 2023.

colored pencils
A new wave of biosimilars are poised to reach the market in the next three years • Source: Alamy

Some of the most enticing commercial opportunities for biosimilar manufacturers and the biggest potential savings to the US health system are approaching in the next three years, and drug makers and other stakeholders are laying the groundwork now for that expansion.

The next wave of biosimilars is expected to prove more competitive than the initial wave, posing new challenges for biosimilar...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip